emerged as a successful treatment strategy for several advanced cancers. Here we demonstrate that SETD2-miR-339 regulates the PD-L1/PD-1 pathways in renal cell cancer.
INTRODUCTION AND OBJECTIVES:
Recent studies suggested that ERb could promote the ccRCC progression, and results from the TCGA database analyses indicate that ERb expression is associated with the ccRCC stage, progression, and a worse overall survival. However, the detailed mechanisms by which ERb regulates the RCC progression remains to be further elucidated. Our new finding indicates that ERb could regulate circRNA to control ccRCC progression. Furthermore, early studies indicated that a subset of miRNAs were either up-or down-regulated in metastatic ccRCC, yet the functions of those RCC metastasis related miRNAs and how they interact with lncRNAs and circRNAs remain to be further elucidated.
METHODS: RCC 786-O, A498, Caki-1 cells were used for the study. Lentiviral system was used for ectopic expression or knockdown of gene expressions. RNA extraction and quantitative Real-Time PCR were applied to determine the mRNA levels. Matrigel transwell and 3 D Invasion Assays were used to test the invasiveness of RCC cells. Chromatin Immunoprecipitation assay (ChIP) was applied to detect the protein-gene promoter (genomic DNA) binding. circRNA-miRNA pull-down assay was used to detect the interaction and function regulation between non-coding RNAs. Preclinical mouse RCC models were used to prove the therapeutic potential of FDA proved anti-estrogen or by targeting the ERregulated signal pathways.
RESULTS: Our data showed higher expressions or activities can promote ccRCC cell invasion. ERb enhanced ccRCC cells invasion via altering the circATP2B1/miR-204-3p axis. This ERb/circATP2B1/ miR204-3p axis could promote ccRCC cell invasion via altering FN1 expression. Supportively, human clinical data show that higher ERb expression is associated with the higher stage and poor prognosis in ccRCC patients. Importantly, preclinical study using in vivo mouse studies confirmed that ERb promotes the ccRCC metastasis via altering the expression and function of circularRNA, circATP2B1.
CONCLUSIONS: Together, our study proved that ERb promotes ccRCC cell invasion by altering the ERb/circATP2B1/miR-204-3p/FN1 axis. These results further suggest that ERb and circular RNA ATP2B1 may be applied as prognostic biomarkers for this disease, and that therapeutic targeting of this newly identified pathway may better prevent ccRCC progression. (tRCC) is a rare kidney neoplasm, however, in patients under 45 years the incidence is up to 15%. Recent studies provided first insights into the genomic underpinnings of tRCC, but additional cohorts are required to fully understand the molecular evolution of these tumors. We performed allele-specific copy-number (ASCN) analysis on nextgeneration sequencing (NGS) data to further investigate the genomic evolution of tRCC. METHODS: We identified 42 patients with tRCC between 1997 and 2017. Diagnosis of tRCC was confirmed with positive immunohistochemistry and/or FISH results. The sequencing cohort consisted of 27 patients. Whole-exome sequencing was performed in 13 of the samples, 14 were sequenced with our institutional panel (MSK-IMPACTÒ). We performed somatic variant calling and ASCN analysis using our bioinformatics pipeline. To infer the relative timing of oncogenic events, we computed clonality estimates, using the purity and ploidy estimates from the copy-number variation (CNV) analysis. Clinical correlates were evaluated using non-parametric hypothesis tests. Survival estimates were produced using the Kaplan-Meier method.
RESULTS: Of the sequencing cohort, a total of 11 men and 11 women had comprehensive mutation and copy-number information. Six patients presented with metastatic disease (22%). The median age was 42.5 years (IQR 33-52); this value was used to stratify patients into old and young groups. The median follow-up time was 27.3 months. The frequent somatic events and translocation binding partners are illustrated in Fig.1a , the frequencies of copy-number events are shown in Fig.1b . Patients older than 42.5 years showed a higher burden of TERT mutations (p[0.21) and an increased rate of CNVs (p[0.11), however, these results were not significant. Overall survival was worse for patients with 9p-loss (p[0.032). The time to recurrence was shorter in patients with 3p-loss (p[0.009) or 15q-loss (p[0.0027). Also, there was a significant association between 4q-loss and metastatic disease at presentation (p[0.009).
CONCLUSIONS: Our data suggests that the genomic landscape of tRCC may vary according to the age at diagnosis. Additional oncogenic events in older patients may drive a more aggressive phenotype. Somatic CNVs seem to play an important role in patient prognosis.
